- News & Analysis
- Home
- Latest News
- Reports
- Podcasts
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 47
Veracyte votes for $318m HalioDx acquisition
Sham Innovation Santé is set to exit the oncology diagnostics test developer in an cash-and-stock acquisition expected to close later this year.
Jun 4, 2021Etsy to devour Depop in $1.62bn deal
Lumar is set to exit the Gen Z-focused social commerce platform in an acquisition by Etsy that comes after about $100m in funding.
Jun 3, 2021Wejo to drive through $800m reverse merger
General Motors and Palantir will support a $100m PIPE deal in connection with a reverse takeover for the vehicular data platform developer.
Jun 2, 2021Daily Deal Round Up: June 1, 2021
Oriola sold part of its stake in telehealth platform developer Doktor.se through a $61.1m round while bicycle marketplace The Pro’s Closet bagged $40m.
Jun 1, 2021Tata Digital buys up majority of BigBasket
The online household items and fresh produce marketplace has sealed a $1.2bn majority acquisition by the Tata unit, enabling Alibaba to exit.
Jun 1, 2021Daily Deal Round Up: May 28, 2021
Lilly Asia Ventures took part in a $78m round for oncology therapy developer BH Med while gifting platform developer Snappy completed a $70m Hearst-backed series C.
May 28, 2021Acorns to grow with reverse takeover plans
The Comcast, PayPal and Rakuten-backed micro-investing service is merging with Nasdaq-listed Pioneer Merger Corp at a $2.2bn post-transaction valuation.
May 28, 2021Tritium ties up $1.2bn reverse merger
The Gilbarco Veeder-Root, Varley Group and Cigna-backed electric vehicle charging technology developer will list through a $1.2bn reverse merger deal.
May 28, 2021Lodo likes the sound of acquisition
Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.
May 28, 2021Effector exercises reverse merger
The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.
May 27, 2021About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


